Dainippon Sumitomo Pharma Reports that Latuda® (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase ...

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression .

W-B nonprofit faces wrongful death suit

John Glenn Popple wandered down to the kitchen a few hours after a site supervisor at the New Hope Community Home in Tunkhannock had tucked him in for the night. Popple - bipolar, autistic and severely mentally disabled - grabbed four or five jelly doug